ClinicalTrials.gg
CompletedNCT01735955Updated Feb 8, 2024Results posted

Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

A Phase 4 interventional study of Nilotinib in Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST) and Acute Lymphoblastic Leukemia (ALL), sponsored by Novartis Pharmaceuticals. Completed at 33 sites in 16 countries. Per ClinicalTrials.gov, last updated 2024-02-08.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
57
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
33rd of 66
57 · median 55
Started
2013
with 10 others
Phase 4
12 of 66
1 open now
Registered
38th of 66
by date
Lead sponsor
35 of 66
Novartis Pharmaceuticals

Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 33rd largest by enrollment, is one of 11 that started in 2013, is one of 12 in phase 4, and was the 38th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About nilotinib

nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

The purpose of this study was to allow continued use of nilotinib in patients who were on nilotinib treatment in a Novartis-sponsored, Oncology Clinical Development \& Medical Affairs (CD\&MA) study and were benefiting from the treatment as judged by the investigator

Read the detailed description

This was a multi-center, open label, single-arm, phase IV study to better characterize the long-term safety of nilotinib in patients treated in Novartis-sponsored studies and who benefited from treatment with nilotinib.

Patients who were enrolled in Novartis-sponsored nilotinib studies, had benefitted from treatment with nilotinib and fulfilled all requirements in the parent study could be enrolled into the current roll-over study.

There was no sample size estimation carried out for this study.

Patients returned to the study center on a quarterly basis (12 weeks ± 1 week) for scheduled visit. Adverse Events (AEs) (non-serious and serious AEs), clinical benefit assessment by investigator and study medication dispensing information were collected.

The original protocol of the current roll-over study was designed to provide continuation of treatment with nilotinib for patients enrolled in nilotinib studies. Therefore, the original protocol did not require AEs (non-serious and serious AEs) to be collected into the clinical database and only required serious adverse events (SAEs) to be collected in the Novartis safety database throughout the study duration.

The scheduled visit frequency was annually.

However, feedback from health authorities stated that all AEs should be collected. To account for this, the protocol was amended in 2016 (Protocol amendment 3 (PA 3)), with the primary objective changed to assess long-term safety of nilotinib. Consequently, PA 3 started to require all AEs (non-serious and serious AEs) to be entered into the clinical database, in addition to the continued SAE collection into the Novartis safety database. At the same time, the scheduled visit frequency was increased from annually to quarterly, and the protocol was also amended to require an investigator assessment of clinical benefit for patients.

03

Conditions studied

  • Chronic Myelogenous Leukemia (CML)
  • Metastatic Gastrointestinal Stromal Tumors (GIST)
  • Acute Lymphoblastic Leukemia (ALL)
  • Receptor Tyrosine Kinase (KIT) Mutated Melanoma

Keywords

  • metastatic gastrointestinal stromal tumors (GIST)
  • Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP),
  • adult
  • Chronic myelogenous leukemia (CML)
  • chronic myeloid leukemia (CML)
  • chronic myelocytic leukemia (CML)
  • Acute Lymphoblastic Leukemia (ALL)
  • Philadelphia chromosome positive
  • Acute Lymphoid Leukemia
  • suboptimal molecular response
  • Tasigna
  • CML
  • GIST
  • nilotinib
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-Patient is currently enrolled in a Novartis-sponsored, Oncology Clinical Development \& Medical Affairs study receiving nilotinib and has fulfilled all their requirements in the parent study -Patient is currently benefiting from the treatment with nilotinib, as determined by the investigator -Patient has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements -Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures -Written obtained prior to enrolling in roll-over study

Exclusion criteria

Exclusion Criteria:

  • Patient has been permanently discontinued from nilotinib treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason - Patient has participated in a Novartis sponsored combination trial where nilotinib was dispensed in combination with another study medication and patient is still receiving combination therapy -Patients who are currently receiving treatment with any medications that have the potential to prolong the or inducing Torsade de Pointes and the treatment cannot be either safely discontinued at least one week prior to nilotinib treatment or switched to a different medication prior to start of nilotinib treatment and for the duration of the study -Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hcG laboratory test. -Women of , defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of during the study and for 30 days after the final dose of nilotinib.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    Nilotinib

    Patients who were on nilotinib treatment in a Novartis-sponsored study (parent study) and were benefiting from nilotinib treatment met the criteria for enrolment into the CAMN107A2409 study and to receive continued nilotinib treatment. The starting dose of nilotinib in the CAMN107A2409 study should have been the same as the last dose administered in the parent study. After the starting dose, the dose of nilotinib was based on the investigator's judgement. The dose of nilotinib should have been ≤ 800 mg/day for adult patients, 230mg/m2 body surface area (BSA) and ≤ 800 mg/day for pediatric patients.

    Drug: Nilotinib

Interventions

  • Patients who were on nilotinib treatment in a Novartis-sponsored study (parent study) and were benefiting from nilotinib treatment met the criteria for enrolment into the CAMN107A2409 study and to receive continued nilotinib treatment. The starting dose of nilotinib in the CAMN107A2409 study should have been the same as the last dose administered in the parent study. After the starting dose, the dose of nilotinib was based on the investigator's judgement. The dose of nilotinib should have been ≤ 800 mg/day for adult patients, 230mg/m2 body surface area (BSA) and ≤ 800 mg/day for pediatric patients.

    Also known as: AMN107

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events and Serious Adverse Events

    An Adverse Event (AE) is any untoward medical occurrence (eg any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product. Serious adverse event (SAE) case data were collected in the Safety Database. Adverse event (AE) data (both non-serious and serious) were collected in the Clinical database. Max. = Maximum Yrs = Years Approx. = Approximately eCRF = electronic Case Report Form Time = timeframe

    Time frame: SAE case data were collected the entire study duration after first dose of study treatment up to a max. time of approx. 10 yrs. AEs (both non-serious and serious) were collected in the eCRF 3 yrs after study initiation up to a max. time of approx. 7 yrs.

Secondary outcomes

  1. Number of Participants With Clinical Benefit From Nilotinib

    Number of patients (pts) with clinical benefit as assessed by investigator. Clinical benefit data were first collected 3 years after study initiation and up to a maximum timeframe of approx. 7 years and 3 months at a patient level (up to Week 528 total at the study level). Pts who discontinued in the first 3 years after study initiation didn't have any clinical benefit data collected. Pts who enrolled in the first 3 years after study initiation only had clinical benefit data collected starting at approx. the third year of the study until the end of the patient's participation in the study. Pts who enrolled after the first 3 years after study initiation had all clinical benefit data collected until the end of the patient's participation in the study. Data for the earlier time points are provided only for later enrolled pts. Data for the later time points are provided only for the earlier enrolled pts. The time point per patient was calculated from the date of first drug intake.

    Time frame: Clinical benefit data were first collected 3 years after study initiation and are reported at baseline, Weeks 24, 48, 72, 96, 144, 192, 240, 288, 336, 384, 432, 480, and 528.

07

Results

Posted Feb 8, 2024

Participant flow

Participant flow — Overall Study
MilestoneNilotinib
Started57
Completed20
Not completed37
Withdrew: Administrative problems1
Withdrew: Patient/guardian decision1
Withdrew: Patient withdrew consent2
Withdrew: Physician decision4
Withdrew: Disease progression24
Withdrew: Adverse event5

Outcome measures

PrimaryNumber of Participants With Adverse Events and Serious Adverse Events

An Adverse Event (AE) is any untoward medical occurrence (eg any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product. Serious adverse event (SAE) case data were collected in the Safety Database. Adverse event (AE) data (both non-serious and serious) were collected in the Clinical database. Max. = Maximum Yrs = Years Approx. = Approximately eCRF = electronic Case Report Form Time = timeframe

Time frame:
SAE case data were collected the entire study duration after first dose of study treatment up to a max. time of approx. 10 yrs. AEs (both non-serious and serious) were collected in the eCRF 3 yrs after study initiation up to a max. time of approx. 7 yrs.
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events and Serious Adverse Events
ParticipantsNilotinib
Adverse Events - total29
Adverse Events - Treatment-related adverse events15
SAEs - total17
SAEs - Treatment-related SAEs2
AEs leading to discontinuation - total3
AEs leading to discontinuation - Treatment-related AEs leading to discontinuation3
SecondaryNumber of Participants With Clinical Benefit From Nilotinib

Number of patients (pts) with clinical benefit as assessed by investigator. Clinical benefit data were first collected 3 years after study initiation and up to a maximum timeframe of approx. 7 years and 3 months at a patient level (up to Week 528 total at the study level). Pts who discontinued in the first 3 years after study initiation didn't have any clinical benefit data collected. Pts who enrolled in the first 3 years after study initiation only had clinical benefit data collected starting at approx. the third year of the study until the end of the patient's participation in the study. Pts who enrolled after the first 3 years after study initiation had all clinical benefit data collected until the end of the patient's participation in the study. Data for the earlier time points are provided only for later enrolled pts. Data for the later time points are provided only for the earlier enrolled pts. The time point per patient was calculated from the date of first drug intake.

Time frame:
Clinical benefit data were first collected 3 years after study initiation and are reported at baseline, Weeks 24, 48, 72, 96, 144, 192, 240, 288, 336, 384, 432, 480, and 528.
Reported as:
Number · Participants
Number of Participants With Clinical Benefit From Nilotinib
ParticipantsNilotinib
Patients with clinical benefit - Baseline15
Patients with clinical benefit - Week 2411
Patients with clinical benefit - Week 4817
Patients with clinical benefit - Week 7211
Patients with clinical benefit - Week 9619
Patients with clinical benefit - Week14423
Patients with clinical benefit - Week 19226
Patients with clinical benefit - Week 24020
Patients with clinical benefit - Week 2889
Patients with clinical benefit - Week 3369
Patients with clinical benefit - Week 3847
Patients with clinical benefit - Week 4326
Patients with clinical benefit - Week 4806
Patients with clinical benefit - Week 5284

Adverse events

Collected over Serious adverse event (SAE) case data were collected in the Safety Database the entire study duration after first dose of study treatment, up to a maximum timeframe of approx. 10 years. Adverse Event (AE) data (both non-serious and serious AEs) were collected in the Clinical Database 3 years after study initiation up to a maximum timeframe of approx. 7 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nilotinib0/57 (0%)17/57 (29.8%)20/57 (35.1%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventNilotinib
Myocardial infarctionCardiac disorders1/57
Myocardial ischaemiaCardiac disorders1/57
TachycardiaCardiac disorders1/57
Abdominal painGastrointestinal disorders1/57
Abdominal pain upperGastrointestinal disorders1/57
Intestinal obstructionGastrointestinal disorders1/57
MelaenaGastrointestinal disorders1/57
Pancreatitis acuteGastrointestinal disorders1/57
CholelithiasisHepatobiliary disorders1/57
COVID-19Infections and infestations1/57
Most frequent other events
Showing 10 of 11
Most frequent other events
EventNilotinib
HeadacheNervous system disorders5/57
COVID-19Infections and infestations4/57
MyalgiaMusculoskeletal and connective tissue disorders4/57
AlopeciaSkin and subcutaneous tissue disorders4/57
Abdominal pain upperGastrointestinal disorders3/57
FatigueGeneral disorders3/57
NasopharyngitisInfections and infestations3/57
Pain in extremityMusculoskeletal and connective tissue disorders3/57
ParaesthesiaNervous system disorders3/57
Oropharyngeal painRespiratory, thoracic and mediastinal disorders3/57

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Nilotinib
<=18 years7
Between 18 and 65 years30
>=65 years20
Age, Continuous
Age, Continuous(years)Nilotinib
Mean53.02 ± 19.278
Sex: Female, Male
Sex: Female, Male(Participants)Nilotinib
Female30
Male27
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Nilotinib
08

Study locations

33 sites
  • Novartis Investigative Site
    Albany, New York 12208, United States
  • Novartis Investigative Site
    Houston, Texas 77030, United States
  • Novartis Investigative Site
    Vienna, A 1090, Austria
  • Novartis Investigative Site
    Vancouver, British Columbia V5Z 4E6, Canada
  • Novartis Investigative Site
    Halifax, Nova Scotia B3H 1V7, Canada
  • Novartis Investigative Site
    Hamilton, Ontario L8V 5C2, Canada
  • Novartis Investigative Site
    Toronto, Ontario M5G1X5, Canada
  • Novartis Investigative Site
    Lille, 59000, France
  • Novartis Investigative Site
    Paris, 75571, France
  • Novartis Investigative Site
    Hong Kong SAR, Hong Kong
  • Novartis Investigative Site
    Budapest, 1062, Hungary
  • Novartis Investigative Site
    Budapest, 1097, Hungary
  • Novartis Investigative Site
    Haifa, 3109601, Israel
  • Novartis Investigative Site
    Bologna, BO 40138, Italy
  • Novartis Investigative Site
    Genova, GE 16147, Italy
  • Novartis Investigative Site
    Modena, MO 41124, Italy
  • Novartis Investigative Site
    Roma, RM 00161, Italy
  • Novartis Investigative Site
    Candiolo, TO 10060, Italy
  • Novartis Investigative Site
    Suwon, Gyeonggi-do 443380, Korea, Republic of
  • Novartis Investigative Site
    Seoul, Korea 05505, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 06351, Korea, Republic of
  • Novartis Investigative Site
    Amsterdam, 1081 HV, Netherlands
  • Novartis Investigative Site
    Leiden, 2300 RC, Netherlands
  • Novartis Investigative Site
    Moscow, 117198, Russian Federation
  • Novartis Investigative Site
    Singapore, 119228, Singapore
  • Novartis Investigative Site
    Singapore, 169608, Singapore
  • Novartis Investigative Site
    Bratislava, 833 10, Slovakia
  • Novartis Investigative Site
    Barcelona, 08041, Spain
  • Novartis Investigative Site
    Malmö, SE-205 02, Sweden
  • Novartis Investigative Site
    Cambridge, London CB2 2QQ, United Kingdom
  • Novartis Investigative Site
    London, SW3 6JJ, United Kingdom
  • Novartis Investigative Site
    Manchester, M20 4BX, United Kingdom
  • Novartis Investigative Site
    Newcastle upon Tyne, NE7 7DN, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2013 to primary completion in Jul 2023, 123 months.

Results were first posted in Feb 2024, 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2012
First posted
Nov 28, 2012
StartActual
Mar 29, 2013
Primary completionActual
Jul 7, 2023
CompletionActual
Jul 7, 2023
Results first posted
Feb 8, 2024
Last update
Feb 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01735955
Responsible party
Sponsor
First posted
Nov 28, 2012
Start date
Mar 29, 2013
Primary completion
Jul 7, 2023
Completion
Jul 7, 2023
Results posted
Feb 8, 2024
Last update
Feb 8, 2024

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilotinib

Start the discussion